Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23667756 | 0.91 | — | — | |
| SCHEMBL16883925 | 0.87 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL14213292 | 0.87 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL14891876 | 0.87 | — | — | |
| SCHEMBL19542925 | 0.84 | TSHR (0.33) | MAPK1 | |
| SCHEMBL12555908 | 0.84 | TSHR (0.33) | MAPK1 | |
| SCHEMBL13538680 | 0.84 | TSHR (0.33) | MAPK1 | |
| SCHEMBL8401131 | 0.83 | — | — | |
| SCHEMBL18455676 | 0.82 | — | — | |
| SCHEMBL9847492 | 0.80 | MAPK1 (0.32) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111932-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2018-04-26 | — | — | US | disclosed |
| US-8329927-B2 | Water-soluble and water-insoluble, ring opening metathesis polymerization products, monomers and related methods | UNIVERSITY OF MASSACHUSETTS (US) | 2012-12-11 | — | — | US | disclosed |
| EP-0650470-A1 | METHOD OF PREPARING POLYOL ALKYL ETHERS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994001389-A1 | METHOD OF PREPARING POLYOL ALKYL ETHERS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111932-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | SCN1B, SCN3A, SCN5A | MAPK1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.